GRAIL (GRAL) Revenue & Revenue Breakdown
GRAIL Revenue Highlights
Latest Revenue (Y)
$147.17M
Latest Revenue (Q)
$36.19M
Main Geography (Y)
UNITED STATES
GRAIL Revenue by Period
GRAIL Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $147.17M | 17.18% |
| 2024-12-31 | $125.59M | 34.90% |
| 2023-12-31 | $93.11M | 67.61% |
| 2022-12-31 | $55.55M | 280.17% |
| 2021-12-31 | $14.61M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
GRAIL generated $147.17M in revenue during NA 2025, up 17.18% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
GRAIL Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $36.19M | 1.83% |
| 2025-06-30 | $35.54M | 11.64% |
| 2025-03-31 | $31.84M | -16.77% |
| 2024-12-31 | $38.25M | 33.51% |
| 2024-09-30 | $28.65M | -10.38% |
| 2024-06-30 | $31.97M | 19.64% |
| 2024-03-31 | $26.72M | -11.89% |
| 2023-12-31 | $30.33M | 46.35% |
| 2023-09-30 | $20.72M | -7.55% |
| 2023-06-30 | $22.41M | 14.11% |
| 2023-04-02 | $19.64M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2019-09-30 | - | - |
GRAIL generated $36.19M in revenue during Q3 2025, up 1.83% compared to the previous quarter, and up 113.21% compared to the same period a year ago.
GRAIL Revenue Breakdown
GRAIL Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 |
|---|---|---|
| Non-US | $8.24M | $14.69M |
| UNITED STATES | $136.76M | - |
| Americas | - | $108.54M |
Latest
GRAIL's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (94.32%), and Non-US (5.68%).
Quarterly Revenue by Country
| Country | Dec 25 | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|---|
| UNITED STATES | $69.98M | $32.57M | $34.21M | - |
| Non-US | $1.31M | $3.31M | $1.17M | $2.45M |
| Americas | - | - | - | $28.70M |
Latest
GRAIL's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (98.16%), and Non-US (1.84%).
GRAIL Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVST | Envista | $2.72B | $669.90M |
| AAPG | ASCENTAGE PHARMA GROUP | $980.65M | $141.22K |
| RARE | Ultragenyx Pharmaceutical | $673.00M | $159.93M |
| IDYA | IDEAYA Biosciences | $218.71M | $207.83M |
| SLNO | Soleno Therapeutics | $190.41M | $66.02M |
| GRAL | GRAIL | $147.17M | $36.19M |
| XENE | Xenon Pharmaceuticals | $7.50M | - |
| APGE | Apogee Therapeutics | - | - |
| CNTA | Centessa Pharmaceuticals | - | - |
| DYN | Dyne Therapeutics | - | - |
| CELC | Celcuity | - | $154.00K |